In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Obalon Therapeutics Inc.

www.obalon.com

Latest From Obalon Therapeutics Inc.

Thirty-five Years Covering Health Care: The More Things Change…

The health care industry has come a long way in the past 35 years, although in some areas very little has changed. Recently retired In Vivo editor Peter Charlish has seen most of the major developments, and in his final feature, he looks back at some of the big stories in a reporting career that began in the early 1980s.

BioPharmaceutical Medical Device

Obesity Firm Allurion Preps For Global Expansion, US Trial With Changes At Top

Intragastric balloon-maker Allurion is making some major changes in its executive suite to support its plan to expand its market reach.

Clinical Trials Business Strategies

Market Intel: Intragastric Balloons And Other Innovations To Inflate Weight Loss Devices Market

The global market for minimally invasive weight loss devices is expected to grow to $290m by 2021, a CAGR of 16%, driven in large part by the rising obesity epidemic and associated Type 2 diabetes. Meddevicetracker expects that enhancements and innovations, particularly in the growing intragastric balloon market, and emerging technologies by smaller companies, will lead the growth in the overall weight loss devices market. In this feature, we'll take a closer look at the overall market and regional landscape and take a deep dive into the fastest-growing intragastric balloon segment, providing key insights from a bariatric surgeon on the pros and cons of these technologies.

Analysis Commercial

Bariatric Devices: Intragastric Balloons To Eclipse Gastric Banding

The market for minimally invasive weight loss devices will reach more than $290 million by 2021, according to a new report from Informa’s Meddevicetracker. Issues relating to laparoscopic adjustable gastric banding systems will result in a greater emphasis being placed on intragastric balloons, which will grow at twice the segment average.

Medical Device Metabolic
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Obalon Therapeutics Inc.
  • Senior Management
  • Kelly Huang, CEO
    William J Plovanic, Pres. & CFO
    Neil Drake, VP, R&D
    Todd Wood, VP, Global Sales
  • Contact Info
  • Obalon Therapeutics Inc.
    Phone: (760) 607-5151
    5421 Avenida Encinas, Ste. F
    Carlsbad, 92008-4410
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register